| Eli Lilly (Suisse) SA - Omvoh 300 mg, solution à diluer pour perfusion | | 68950 | | 01 | | Omvoh 300 mg | | solution à diluer pour perfusion | | L04AC24 | | Mirikizumab | | 30.11.2023 | | |
| | Composition | | mirikizumabum 300 mg, histidinum, histidini hydrochloridum monohydricum, natrii citras dihydricus, acidum citricum, natrii chloridum, mannitolum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 15 ml corresp. natrium 17.969 mg. | | Packungsbestandteile | | Concentrate for infusion | | | | | | | | Active Agent | Dose |
|---|
| Mirikizumabum | 300mg / 15ml |
| | BAG: Active Agent | Dose |
|---|
| Mirikizumabum | 300 mg |
| | | | Inactive agents |
|---|
| Acidum Citricum | | Histidin Hydrochloride Monohydrate | | Histidine | | Mannitol | | Sodium Chloride | | Natrii Citras Dihydricus | | Polysorbatum 80 |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | 1126.23 | 1241.25 | B | SL | No |
|
|
